MedTrace Logo

Epco, Zanu, Ritux for R/R FL or MZL

NCT06563596 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-02-19

No results posted yet for this study

Summary

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL).

* The names of the study drugs involved in this research study are:
* Epcoritamab (a type of antibody)
* Zanubrutinib (a type of Bruton tyrosine kinase inhibitor)
* Rituximab (a type of monoclonal antibody)

Conditions

Interventions

DRUG

Zanubrutinib

Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.

DRUG

Rituximab

Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.

DRUG

Epcoritamab

Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.

Sponsors & Collaborators

  • BeiGene

    collaborator INDUSTRY

  • Genmab

    collaborator INDUSTRY

  • Reid Merryman, MD

    lead OTHER

Principal Investigators

  • Reid Merryman, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-21
Primary Completion
2028-03-01
Completion
2030-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06563596 on ClinicalTrials.gov